{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:04:02Z","timestamp":1782299042861,"version":"3.54.5"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,14]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Latent tuberculosis (TB) infection screening before inducing anti-tumor necrosis factor (anti-TNF) alpha agents is important to prevent TB reactivation. However, latent TB infection reactivation may still occur, and the ideal therapeutic strategy for patients with inflammatory bowel disease (IBD) who develop active TB infection has not been established. Vedolizumab (VDZ) has a good safety profile, with low incidence rates of serious infections. However, its safety in patients with latent TB infection reactivation associated with anti-TNF-alpha agents remains unknown.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 21-year-old Vietnamese male patient presented to our hospital with hemorrhagic stool. He had no personal or family history of IBD or TB.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Colonoscopy revealed multiple longitudinal ulcers and a cobblestone appearance in the terminal ileum, as well as multiple small erosions and aphtha throughout the colon. Computed tomography revealed a right lung nodular lesion. Serological interferon-gamma release assay and several culture tests were all negative. Thus, he was diagnosed with ileocolonic Crohn\u2019s disease (CD) without TB.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The intravenous anti-TNF-alpha agent administration with an immunomodulator was initiated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Computed tomography revealed nodular lesion expansion at the right lung, and serological interferon-gamma release assay was positive. He was diagnosed with latent TB infection reactivation. Anti-TNF-alpha agent with an immunomodulator was immediately discontinued, and anti-TB therapy was initiated. His endoscopic findings were still active, and VDZ was selected for maintenance therapy because VDZ has a favorable safety profile with low incidence rates of serious infections. Consequently, mucosal healing was achieved without active TB relapse.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This case report presented a patient in whom VDZ was continued as maintenance therapy without inducing TB relapse in a patient with CD who developed latent TB infection reactivation associated with anti-TNF-alpha agents and summarized the safety profile of VDZ for patients with IBD with active or latent TB infection. VDZ may be a safe option for induction and maintenance therapy in patients with CD, even in cases with latent TB infection reactivation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000034331","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T16:21:41Z","timestamp":1689697301000},"page":"e34331","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["The safety of vedolizumab in a patient with Crohn\u2019s disease who developed anti-TNF-alpha agent associated latent tuberculosis infection reactivation: A case report"],"prefix":"10.1097","volume":"102","author":[{"given":"Yuya","family":"Sugiyama","sequence":"first","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5448-4766","authenticated-orcid":false,"given":"Nobuhiro","family":"Ueno","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Asahikawa Medical University Hospital, Asahikawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shion","family":"Tachibana","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Murakami","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Sakatani","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Ando","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Kashima","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Moriichi","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikatsu","family":"Okumura","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikihiro","family":"Fujiya","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis.","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/rheumatology\/keu172","article-title":"Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies.","volume":"53","author":"Souto","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease.","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"Suppl 3","key":"R5-20250504","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults [published correction appears in Gut. 2021 Apr;70(4):1].","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/jgh.15185","article-title":"Asian Organization for Crohn\u2019s and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia.","volume":"36","author":"Ran","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5217\/ir.2018.16.1.4","article-title":"Asian Organization for Crohn\u2019s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment.","volume":"16","author":"Park","year":"2018","journal-title":"Intest Res"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/ecco-jcc\/jjw022","article-title":"Tuberculosis in anti-tumour necrosis factor-treated inflammatory bowel disease patients after the implementation of preventive measures: compliance with recommendations and safety of retreatment.","volume":"10","author":"Carpio","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease.","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00408-016-9872-5","article-title":"Interferon-gamma release assays for the diagnosis of tuberculosis: a systematic review and meta-analysis.","volume":"194","author":"Lu","year":"2016","journal-title":"Lung"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.pulmoe.2019.11.001","article-title":"Host factors associated to false negative and indeterminate results in an interferon-\u03b3 release assay in patients with active tuberculosis.","volume":"26","author":"Santos","year":"2020","journal-title":"Pulmonology"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apt.13475","article-title":"Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn\u2019s disease.","volume":"43","author":"Shah","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/apt.16060","article-title":"Long-term safety of vedolizumab for inflammatory bowel disease.","volume":"52","author":"Loftus","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/ibd\/izy153","article-title":"Low frequency of opportunistic infections in patients receiving Vedolizumab in clinical trials and post-marketing setting.","volume":"24","author":"Ng","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ecco-jcc\/jjz137","article-title":"The safety profile of vedolizumab in ulcerative colitis and Crohn\u2019s disease: 4 years of global post-marketing data.","volume":"14","author":"Cohen","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis.","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.cgh.2016.02.016","article-title":"Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease.","volume":"14","author":"Amiot","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1093\/ibd\/izy133","article-title":"Outcomes of treatment for latent tuberculosis infection in patients with inflammatory bowel disease receiving biologic therapy.","volume":"24","author":"Ramos","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"670242","DOI":"10.3389\/fmed.2021.670242","article-title":"Frequency of positive conversion of interferon-gamma release assay results among patients with inflammatory bowel disease treated with non-tumor necrosis factor inhibitors.","volume":"8","author":"Kim","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.3346\/jkms.2022.37.e107","article-title":"The risk of tuberculosis in patients with inflammatory bowel disease treated with Vedolizumab or Ustekinumab in Korea.","volume":"37","author":"Choi","year":"2022","journal-title":"J Korean Med Sci"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"251","DOI":"10.12701\/yujm.2020.00878","article-title":"Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab.","volume":"38","author":"Choi","year":"2021","journal-title":"Yeungnam Univ J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:20:04Z","timestamp":1746321604000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":21,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034331","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,14]]}}}